Investor Home

Corporate Profile

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

We have three internally-developed late-stage clinical drug candidates:

  • Zanubrutinib (BGB-3111) — an investig...more >
Stock Quotemore >
BGNE (American Depositary Shares)

$136.64

 0.05 (0.04%)

02/16/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium - February 9, 2018
CAMBRIDGE, Mass., and BEIJING, China, Feb. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More
BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference - February 7, 2018
CAMBRIDGE, Mass. and BEIJING, China, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts